Nearly 4% of patients harbored mutations in PDGFRA and MET each and 3% in ZFB1, COL3A1, and COL1A2. Next, we determined CNV in CRGs, and the results revealed the highest number of CNV gains in CTSK, S100A4, and CTHRC1 in patients with BLCA (Figure 1B). The gene discussed is MET; the disease is bladder transitional cell carcinoma.